[Pubmed] Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 cases
Posté : 02 févr. 2023 12:00
Anticancer Drugs. 2022 Dec 5. doi: 10.1097/CAD.0000000000001473. Online ahead of print.
ABSTRACT
The optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. Patients with progressive disease after failure of platinum-based chemotherapy were enrolled in this study. Anlotinib was orally taken once a day at an initial dose of 12 mg (10 mg when body weight
Source: https://pubmed.ncbi.nlm.nih.gov/3672989 ... t6+86293ac